Rigshospitalet
Rigshospitalet is recorded as a service provider in 16 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 16 of 16 trials · Latest update first
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/MOIRAI)
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
Personalized, CT-guided antithrombotic therapy versus standard antiplatelet therapy to reduce thromboembolic and bleeding events in non-atrial fibrillation patients after transcatheter aortic valve implantation: a pragmatic, international, multicentre, randomized clinical trial (POPular ATLANTIS trial)
Sponsor St Antonius Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Sponsor Karolinska University Hospital
- Start (EU)
- Latest update
- Estimated end
The DEXA-PSYCH Study: Dexamethasone Repurposing for Moderate to Severe Depression - A Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Trial
Sponsor Region Hovedstadens Psykiatriske
- Start (EU)
- Latest update
- Estimated end
- Not reported
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
Sponsor Charite Universitaetsmedizin Berlin KöR
- Start (EU)
- Not reported
- Latest update
- Estimated end
An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including a randomized phase III study evaluating the non-inferiority of three courses of high-dose chemotherapy (HDCT) compared to focal radiotherapy as consolidation therapy
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
Luteal phase support following letrozole treatment in women undergoing intrauterine insemination: a multicenter randomized trial
Sponsor Region Midtjylland
- Start (EU)
- Latest update
- Estimated end
- Not reported
Safety and efficacy of mitapivat sulfate in adult patients with erythrocyte membranopathies
Sponsor Eurobloodnet Association
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II-TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ZANUBRUTINIB (BGB-3111), A BTK INHIBI-TOR, PLUS TISLELIZUMAB (BGB-A317), A PD-1 INHIBITOR, WITH AND WITH-OUT SONROTOCLAX (BGB-11417), A BCL2 INHIBITOR, FOR TREATMENT OF PATIENTS WITH RICHTER TRANSFORMATION - CLL-RT1-Trial
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
- Not reported
HOVON 141 CLL: A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations.
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
- Not reported
Intraglandular treatment with adipose derived mesenchymal stem cells in patients with xerostomia due to Sjögrens syndrome (ASSIX)
Sponsor Rigshospitalet
- Start (EU)
- Latest update
- Estimated end
- Not reported
TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A Prospective, randomised-controlled, double-dummy, double-blind phase 3 multi-centre trial of TNK 0.25 mg/kg + placebo vs. ASA + placebo (2 arms with 1:1 block randomisation)
Sponsor Oslo University Hospital HF
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Rigshospitalet?
The 2026-10-09 snapshot links Rigshospitalet to 16 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Project management, Regulatory services, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Rigshospitalet?
The most frequently recorded therapeutic areas are Haematological Malignancies, Cardiology, Gynecology, Neurology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Rigshospitalet conducted?
The linked trials record locations in 20 countries, including Denmark, Netherlands, Germany, Belgium, Finland. These are trial locations, not confirmed office locations or countries where Rigshospitalet delivered services.
What can this page tell me about Rigshospitalet's trial experience?
Browse 16 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Rigshospitalet. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Rigshospitalet